Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

(2013) A. Heine et al.   BLOOD

An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor

(2013) Nicholas G. Wysham et al.   CHEST

Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib

(2013) Rowan Wathes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bilateral Toxoplasmosis Retinitis Associated with Ruxolitinib

(2013) Roger A. Goldberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors

(2012) Anna Yarilina et al.   ARTHRITIS AND RHEUMATISM

Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation

(2011) Jordan S. Fridman et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE